IPA / ImmunoPrecise Antibodies Ltd. - SEC-Einreichungen, Jahresbericht, Proxy Statement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2026. Commission File Number: 001-39530

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2026. Commission File Number: 001-39530 MindWalk Holdings Corp. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by check mark

MindWalk's Preclinical Dengue Data Support a HYFT® Computational Prediction: Immunogens Designed on the Predicted Target Elicited Cross-Reactive Antibodies Against Antigens of All Four Dengue Serotypes, Reproduced Across Two Independent Campaigns HYF

99.1 MindWalk's Preclinical Dengue Data Support a HYFT® Computational Prediction: Immunogens Designed on the Predicted Target Elicited Cross-Reactive Antibodies Against Antigens of All Four Dengue Serotypes, Reproduced Across Two Independent Campaigns HYFT® technology computationally identified and prioritized a pan-serotype dengue target before immunization. Preclinical data support the predictio

MindWalk Holdings Deploys Pandemic Response Platform via HYFT® Technology as Ebola and Hantavirus Outbreaks Expose the Limits of Strain-Specific Coverage

99.1 MindWalk Holdings Deploys Pandemic Response Platform via HYFT® Technology as Ebola and Hantavirus Outbreaks Expose the Limits of Strain-Specific Coverage AUSTIN, Texas — May 27, 2026 (BUSINESS WIRE) — MindWalk Holdings Corp. (NASDAQ: HYFT), a bio-native AI therapeutic research and technology company, today announced the launch of its Pandemic Response Platform, a deployment configuration of t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2026. Commission File Number: 001-39530 M

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2026. Commission File Number: 001-39530 MindWalk Holdings Corp. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by check mark w

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2026. Commission File Number: 001-39530 M

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2026. Commission File Number: 001-39530 MindWalk Holdings Corp. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by check mark w

The Biology Came First.

99.1 The Biology Came First. Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company's work today. AUSTIN, TX — May 2026 — MindWalk Holdings Corp. (NASDAQ: HYFT) MindWalk Hold

SEDI INSIDER ACTIVITY REPORT

99.1 SEDI INSIDER ACTIVITY REPORT Period: March 18-27, 2026 | Source: SEDI Issuer No. 5542 | All prices USD (NASDAQ) WEEK SUMMARY Total Shares Acquired +66,500 common shares (open market) Total Capital Deployed USD $77,024 Average Price $1.1583 per share Trading Days 3 (March 18, 19, 27, 2026) Other Activity RSU grants: 225,000 to T. Lynch (2025-10-29), 185,000 to S. Areglado (2025-10-29); initial

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2026. Commission File Number: 001-39530

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2026. Commission File Number: 001-39530 MindWalk Holdings Corp. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by check mark

Tx Date

99.1 SEDI INSIDER ACTIVITY REPORT Period: March 16–20, 2026 | Source: SEDI Issuer No. 5542 | All prices USD (NASDAQ) WEEK SUMMARY Total Shares Acquired +60,000 common shares (open market) Total Capital Deployed USD $73,238 Average Price $1.2178 per share Trading Days 3 consecutive (March 16, 17, 18, 2026) Other Activity No other SEDI transactions filed during the week ending March 21, 2026 TRANSAC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2026. Commission File Number: 001-39530

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2026. Commission File Number: 001-39530 MindWalk Holdings Corp. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by check mark

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2026. Commission File Number: 001-39530

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2026. Commission File Number: 001-39530 MindWalk Holdings Corp. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by check mark

MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results Third Consecutive Quarter of Year-Over-Year Revenue Growth | First Annual Enterprise LensAI™ Platform Contract | Launch of B cell Llama™ Nanobody Discovery Platform

99.1 MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results Third Consecutive Quarter of Year-Over-Year Revenue Growth | First Annual Enterprise LensAI™ Platform Contract | Launch of B cell Llama™ Nanobody Discovery Platform AUSTIN, TX, March 12, 2026 — MindWalk Holdings Corp. (Nasdaq: HYFT), a Bio-Native AI company focused on biologics discovery and AI-driven drug development, today rep

MINDWALK HOLDINGS CORP. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the three and nine months ended January 31, 2026 and 2025 (Unaudited - Expressed in Canadian Dollars)

Exhibit 99.2 MINDWALK HOLDINGS CORP. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the three and nine months ended January 31, 2026 and 2025 (Unaudited - Expressed in Canadian Dollars) MINDWALK HOLDINGS CORP. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Unaudited - Expressed in Canadian dollars) (in thousands) Note January 31, 2026 $ April 30, 2025 $ ASSETS Current as

Form 52-109F2 Certification of Interim Filings Full Certificate

Exhibit 99.3 Form 52-109F2 Certification of Interim Filings Full Certificate I, Jennifer Bath, Chief Executive Officer, MindWalk Holdings Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of MindWalk Holdings Corp. (the “issuer”) for the interim period ended January 31, 2026. 2. No misrepresentations: Based on m

Three Months Ended ($)

MINDWALK HOLDINGS CORP. MANAGEMENT DISCUSSION AND ANALYSIS FOR THE THREE AND NINE MONTHS ENDED JANUARY 31, 2026 Exhibit 99.1 The following Management’s Discussion and Analysis (“MD&A”) should be read in conjunction with the unaudited condensed interim consolidated financial statements of MindWalk Holdings Corp. (the "Company” or, “MindWalk” for the three and nine months ended January 31, 2026, tog

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2026. Commission File Number: 001-39530

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2026. Commission File Number: 001-39530 MindWalk Holdings Corp. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by check mark

Form 52-109F2 Certification of Interim Filings Full Certificate

Exhibit 99.4 Form 52-109F2 Certification of Interim Filings Full Certificate I, R. Scott Areglado, Chief Financial Officer, MindWalk Holdings Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of MindWalk Holdings Corp. (the “issuer”) for the interim period ended January 31, 2026. 2. No misrepresentations: Based

MindWalk Announces B Cell Llama™, a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era Peer-reviewed study in ACS Biomacromolecules demonstrates modular VHH potency, cross-variant therapeutic activity, and a newly described

99.1 MindWalk Announces B Cell Llama™, a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era Peer-reviewed study in ACS Biomacromolecules demonstrates modular VHH potency, cross-variant therapeutic activity, and a newly described immune-priming mechanism; MindWalk holds first right to commercialize jointly developed intellectual property AUSTIN, TX | MindWalk Holdings Corp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2026. Commission File Number: 001-39530

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2026. Commission File Number: 001-39530 MindWalk Holdings Corp. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by check mark

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2026. Commission File Number: 001-39530

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2026. Commission File Number: 001-39530 MindWalk Holdings Corp. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by check mark

MindWalk Holdings Corp. to Report Third Quarter Fiscal Year 2026 Financial Results on March 12, 2026 The Company to host an earnings conference call via webcast

99.1 MindWalk Holdings Corp. to Report Third Quarter Fiscal Year 2026 Financial Results on March 12, 2026 The Company to host an earnings conference call via webcast AUSTIN, Texas – MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced that it will report financial results for the third quarter of fiscal ye

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2026. Commission File Number: 001-395

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2026. Commission File Number: 001-39530 MindWalk Holdings Corp. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by check ma

MindWalk Applies HYFT® Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics

99.1 MindWalk Applies HYFT® Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics AUSTIN, Texas – MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced an application of its proprietary HYFT® technology designed to identify functional adjacency - meaning different mo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2026. Commission File Number: 001-395

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2026. Commission File Number: 001-39530 MindWalk Holdings Corp. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by check ma

MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease

99.1 MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease VICTORIA, British Columbia — MindWalk Holdings Corp. (“MindWalk” or the “Company”) (Nasdaq: HYFT) today announced the discovery and validation of monoclonal antibodies and intrabodies that selectively target misfolded, pathogenic TDP-43, a disease-driving protein implicat

MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight

99.1 MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight Validated Across Influenza A and Influenza B, Including H3N2 Subclade K and Zoonotic Influenza A Subtypes H5, H7, H9 AUSTIN, Texas – January 9th, 2026 - MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced an advance

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2026. Commission File Number: 001-395

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2026. Commission File Number: 001-39530 MindWalk Holdings Corp. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by check ma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2025. Commission File Number: 001-39

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2025. Commission File Number: 001-39530 MindWalk Holdings Corp. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by check m

Three Months Ended ($)

MINDWALK HOLDINGS CORP. MANAGEMENT DISCUSSION AND ANALYSIS FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2025 Exhibit 99.1 The following Management’s Discussion and Analysis (“MD&A”) should be read in conjunction with the unaudited condensed interim consolidated financial statements of MindWalk Holdings Corp. (the "Company” or, “MindWalk” for the three and six months ended October 31, 2025, toget

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2025. Commission File Number: 001-39

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2025. Commission File Number: 001-39530 MindWalk Holdings Corp. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by check m

MINDWALK HOLDINGS CORP. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the three and six months ended October 31, 2025 and 2024 (Unaudited - Expressed in Canadian Dollars)

Exhibit 99.2 MINDWALK HOLDINGS CORP. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the three and six months ended October 31, 2025 and 2024 (Unaudited - Expressed in Canadian Dollars) MINDWALK HOLDINGS CORP. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Unaudited - Expressed in Canadian dollars) (in thousands) Note October 31, 2025 $ April 30, 2025 $ ASSETS Current ass

MindWalk Reports Record Growth and Announces Strategic Progress on Its AI Asset Pipeline

MindWalk Reports Record Growth and Announces Strategic Progress on Its AI Asset Pipeline VICTORIA, British Columbia – December 15, 2025 – MindWalk (NASDAQ: HYFT), a BioNative AI biotherapeutic research and technology company combining in silico and wet lab operations for biologics discovery and development, today announced financial results for the second quarter of fiscal 2026 and provided updates on its AI driven asset pipeline and strategic initiatives.

Form 52-109F2 Certification of Interim Filings Full Certificate

Exhibit 99.3 Form 52-109F2 Certification of Interim Filings Full Certificate I, Jennifer Bath, Chief Executive Officer, MindWalk Holdings Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of MindWalk Holdings Corp. (the “issuer”) for the interim period ended October, 31, 2025. 2. No misrepresentations: Based on

Form 52-109F2 Certification of Interim Filings Full Certificate

Exhibit 99.4 Form 52-109F2 Certification of Interim Filings Full Certificate I, R. Scott Areglado, Chief Financial Officer, MindWalk Holdings Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of MindWalk Holdings Corp. (the “issuer”) for the interim period ended October 31, 2025. 2. No misrepresentations: Based

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2025. Commission File Number: 001-39

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2025. Commission File Number: 001-39530 MindWalk Holdings Corp. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by check m

MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2026 on December 15, 2025 The Company to host an earnings conference call via webcast

99.1 MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2026 on December 15, 2025 The Company to host an earnings conference call via webcast AUSTIN, Texas – MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced that it will host a conference ca

MindWalk CTO Dr. Dirk Van Hyfte to Join Fireside Chat at AI Drug Discovery & Development Summit 2025

99.1 MindWalk CTO Dr. Dirk Van Hyfte to Join Fireside Chat at AI Drug Discovery & Development Summit 2025 AUSTIN, Texas-(BUSINESS WIRE) - MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), a Bio-Native AI company, today announced that Dr. Dirk Van Hyfte, Chief Technology Officer, will participate in a fireside chat during the Biology Session at the AI Drug Discovery & D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2025. Commission File Number: 001-39

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2025. Commission File Number: 001-39530 MindWalk Holdings Corp. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by check m

MindWalk Holdings Corp. Up to U.S.$30,000,000 Common Shares

PROSPECTUS SUPPLEMENT (To Prospectus dated July 14, 2023) Filed Pursuant to Rule 424(b)(5) Registration No.

SALES AGREEMENT

SALES AGREEMENT November 7, 2025 JonesTrading Institutional Services LLC 325 Hudson Street, 6th Floor New York, New York 10013 Ladies and Gentlemen: MindWalk Holdings Corp.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2025. Commission File Number: 001

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2025. Commission File Number: 001-39530 MindWalk Holdings Corp. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8, Canada (Address of principal executive office) Indicate

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2025. Commission File Number: 001-39

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2025. Commission File Number: 001-39530 MindWalk Holdings Corp. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check mark

MindWalk Holdings Corp. (the “Company”) REVISED STATEMENT OF EXECUTIVE COMPENSATION for the fiscal year ended April 30, 2025 Dated as of October 8, 2025

MindWalk Holdings Corp. (the “Company”) REVISED STATEMENT OF EXECUTIVE COMPENSATION for the fiscal year ended April 30, 2025 Dated as of October 8, 2025 All monetary amounts herein are expressed in Canadian Dollars (“$”) unless otherwise stated. For the purpose of this section: “NEO” or “named executive officer” means each of the following individuals: (a) each individual who, in respect of the Co

Report of Voting Results Submitted Pursuant to Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations

Report of Voting Results Submitted Pursuant to Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations In accordance with Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations, this report describes the matters voted upon and the outcome of the votes at the annual general meeting of shareholders of MindWalk Holdings Corp. (the "Corporation") held on

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2025. Commission File Number: 001-395

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2025. Commission File Number: 001-39530 MindWalk Holdings Corp. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check mark w

MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy

99.1 MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy AUSTIN, Texas - MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), bio-native AI company today announces the appointment of industry veteran R. Scott Areglado as Chief Financial Officer (CFO), effective October 20, 2025. “Scott’s extensive e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2025. Commission File Number: 001-395

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2025. Commission File Number: 001-39530 MindWalk Holdings Corp. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check mark w

IMMUNOPRECISE ANTIBODIES LTD. 2025 STOCK INCENTIVE PLAN

IMMUNOPRECISE ANTIBODIES LTD. 2025 STOCK INCENTIVE PLAN Section 1. Purpose. The purpose of the Plan is to promote the interests of the Company and its shareholders by aiding the Company in attracting and retaining employees, officers, consultants, independent contractors, advisors and non-employee Directors capable of assuring the future success of the Company, to offer such persons incentives to

Table 1: Newly Registered Securities

Calculation of Filing Fee Tables S-8 MindWalk Holdings Corp. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Shares, no par value per share Other 5,620,254 $ 1.71 $ 9,610,634.34 0.0001381 $ 1,327.23 Total Offeri

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MindWalk Holdings Corp. (Exact name of registrant as specified in its charter) British Columbia, Canada Not Applicable (State or other jurisdiction of (I.R.S. Employer Identification No.) incorporation or organization) Industrious 823 Congress Ave Suite 300 Austi

MindWalk Appoints Dr. Thomas W. Lynch as Chief Business Officer to Accelerate Commercial Expansion

99.1 MindWalk Appoints Dr. Thomas W. Lynch as Chief Business Officer to Accelerate Commercial Expansion AUSTIN, Texas - MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), a Bio-Native AI company today announced the appointment of industry veteran Thomas W. Lynch, Ph.D. as Chief Business Officer (CBO), effective October 20, 2025. “Tom’s combination of biotech depth and s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2025. Commission File Number: 001-395

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2025. Commission File Number: 001-39530 MindWalk Holdings Corp. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check mark w

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2025. Commission File Number: 001-395

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2025. Commission File Number: 001-39530 MindWalk Holdings Corp. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check mark w

Unaudited Pro Forma Financial Information

Exhibit 99.1 Unaudited Pro Forma Financial Information Overview On August 6, 2025 MindWalk Holdings Corp. (formerly “ImmunoPrecise Antibodies Ltd.”) (NASDAQ: HYFT) (“MindWalk” or the “Company”), a biotherapeutics company delivering advanced solutions in biologics and drug discovery, announced the divesture of its Netherlands-based subsidiary, ImmunoPrecise Antibodies (Europe) B.V. (“IPA Europe”),

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2025. Commission File Number: 001-395

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2025. Commission File Number: 001-39530 MindWalk Holdings Corp. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check mark w

MindWalk Announces Share Repurchase Program

99.1 MindWalk Announces Share Repurchase Program AUSTIN, Texas – MindWalk Holdings Corp. (“MindWalk” or the “Company”) (NASDAQ: “HYFT”), a bio-native AI company , today announced that to underscore its confidence in MindWalk's future development and growth prospects, its Board of Directors (the “Board”) has authorized a share repurchase program under which MindWalk may repurchase up to 2.3 million

MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity Company builds on earlier GLP-1 success with breakthrough AI-led insights into aging biology -- targeting the widely projected $60B longevity

MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity Company builds on earlier GLP-1 success with breakthrough AI-led insights into aging biology - targeting the widely projected $60B longevity therapeutics market HYFT®-driven discovery supports co-administration of MindWalk’s proprietary companion therapeutic with the Company’s GLP-1 receptor agonist AUSTIN, Texas-(BUSINESS WIRE) - MindWalk Holdings Corp.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2025. Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2025. Commission File Number: 001-39530 MindWalk Holdings Corp. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check mark

Form 52-109F2 Certification of Interim Filings Full Certificate

Exhibit 99.3 Form 52-109F2 Certification of Interim Filings Full Certificate I, Jennifer Bath, Chief Executive Officer, MindWalk Holdings Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of MindWalk Holdings Corp. (the “issuer”) for the interim period ended July, 31, 2025. 2. No misrepresentations: Based on my

MindWalk Holdings Corp.TM (formerly ImmunoPrecise AntibodiesTM) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet Company to hold conference call on September 15, 2025 at 10:3

MindWalk Holdings Corp.TM (formerly ImmunoPrecise AntibodiesTM) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet Company to hold conference call on September 15, 2025 at 10:30 ET to review corporate highlights Austin, Texas, September 15, 2025 – MindWalk Holdings Corp.™ (“MindWalk™”, “Company”, “we” or “us”) (NASDAQ: HYFT)

Three Months Ended ($)

MINDWALK HOLDINGS CORP. MANAGEMENT DISCUSSION AND ANALYSIS FOR THE THREE MONTHS ENDED JULY 31, 2025 AND JULY 31, 2024 Exhibit 99.1 The following Management’s Discussion and Analysis (“MD&A”) should be read in conjunction with the unaudited condensed interim consolidated financial statements of MindWalk Holdings Corp. (the "Company”, “MindWalk” for the three months ended July 31, 2025, together wit

MINDWALK HOLDINGS CORP. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the three months ended July 31, 2025 and 2024 (Unaudited - Expressed in Canadian Dollars)

Exhibit 99.2 MINDWALK HOLDINGS CORP. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the three months ended July 31, 2025 and 2024 (Unaudited - Expressed in Canadian Dollars) MINDWALK HOLDINGS CORP. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Unaudited - Expressed in Canadian dollars) (in thousands) Note July 31, 2025 $ April 30, 2025 $ ASSETS Current assets Cash 4,897

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2025. Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2025. Commission File Number: 001-39530 MindWalk Holdings Corp. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check mark

Form 52-109F2 Certification of Interim Filings Full Certificate

Exhibit 99.4 Form 52-109F2 Certification of Interim Filings Full Certificate I, Joseph Scheffler, Interim Chief Financial Officer, MindWalk Holdings Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of MindWalk Holdings Corp. (the “issuer”) for the interim period ended July, 31, 2025. 2. No misrepresentations: B

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2025. Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2025. Commission File Number: 001-39530 MindWalk Holdings Corp. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check mark

MindWalk to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2026 on September 15, 2025 The Company to host an earnings conference call via webcast

MindWalk to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2026 on September 15, 2025 The Company to host an earnings conference call via webcast AUSTIN, Texas – MindWalk (NASDAQ: HYFT) (“HYFT” or the “Company”), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year end 2026, on Monday, September 15, 2025, at 10:30 am Eastern Time.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2025. Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by chec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2025. Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by chec

ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT” An Evolution in Name, Structure, and Strategy Reflecting the Company’s AI-Driven Platform and Bio-Native Discovery Vision

ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT” An Evolution in Name, Structure, and Strategy Reflecting the Company’s AI-Driven Platform and Bio-Native Discovery Vision AUSTIN, TEXAS  – ImmunoPrecise Antibodies Ltd.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2025. Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by chec

ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York

ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York AUSTIN, Texas, September 2nd, 2025 – ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), today announced that it will participate in the 27th Annual H.C. Wainwright Global Investment Conference, taking place September 8th through September 10th, 2025. Dr. Jennifer Bat

ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation Manufacturing of validated dengue epitope underway; proprietary immunization studies in rabbit model to assess monoclon

ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation Manufacturing of validated dengue epitope underway; proprietary immunization studies in rabbit model to assess monoclonal antibody (mAb) responses.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025. Commission File Number: 001-3953

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check m

ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation

ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation AUSTIN, TEXAS  – ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a biotherapeutics company delivering advanced solutions in biologics and drug discovery, today announced the successful sale of its Netherlands-based subsidiary, ImmunoPrecise Antibodies (Europe) B.V. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025. Commission File Number: 001-3953

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check m

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025. Commission File Number: 001-3953

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check m

Date: August 1, 2025

ImmunoPrecise Antibodies Ltd. 3204-4464 Markham Street Victoria, BC, Canada V8Z 7X8 PH: +1 (250) 483-0308 Website: www.ipatherapeutics.com Email: [email protected] Date: August 1, 2025 To: All Canadian Securities Regulatory Authorities NASDAQ Exchange Subject: IMMUNOPRECISE ANTIBODIES LTD. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders fo

or at such other address and/or email and/or to the attention of such other person as the recipient party has specified by written notice given to each other party three (3) Business Days prior to the effectiveness of such change. Written confirmati

Exhibit 2.2 THE SECURITIES REPRESENTED BY THIS CERTIFICATE AND THOSE SECURITIES INTO WHICH THEY ARE CONVERTIBLE HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES AND THOSE SECURITIES INTO WHICH THEY ARE CONVERTIBLE HAVE BEEN ACQUIRED SOLELY FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWAR

DISCLOSURE, CONFIDENTIALITY & TRADING POLICY

DISCLOSURE, CONFIDENTIALITY & TRADING POLICY The Policy: This policy establishes procedures which are designed to: (i) permit the disclosure of information about IMMUNOPRECISE ANTIBODIES LTD.

The obligation of the Company hereunder to issue and sell the Convertible Debentures to each Buyer at each Closing is subject to the satisfaction, at or before each Closing Date, of each of the following conditions, provided that these conditio

Exhibit 4.5 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of July 16, 2024, is between IMMUNOPRECISE ANTIBODIES LTD., a British Columbia corporation, with principal executive offices located at 3204-4464 Markham Street, Victoria, BC V8Z 7X8 (the “Company”), and each of the investors listed on the Schedule of Buyers attached as Schedule I hereto (indi

CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of ImmunoPrecise Antibodies Ltd. (the “Company”) on Form 20-F for the period ended April 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joseph Scheffler, Interim Chief Financial Officer

REGISTRATION RIGHTS AGREEMENT

Exhibit 4.6 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of July 16, 2024 is made by and between YA II PN, LTD., a Cayman Islands exempt limited partnership (the “Investor”), and IMMUNOPRECISE ANTIBODIES LTD., a British Columbia corporation (the “Company”). The Investor and the Company may be referred to herein individually as a “Party” and collecti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025. Commission File Number: 001-39530

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check mar

CERTIFICATION

Exhibit 12.1 CERTIFICATION I, Jennifer Bath, certify that: 1. I have reviewed this annual report on Form 20-F of ImmunoPrecise Antibodies Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with

GLOBAL GUARANTY AGREEMENT

Exhibit 4.7 GLOBAL GUARANTY AGREEMENT This Guaranty is made as of July 16, 2024 by ImmunoPrecise Antibodies (Canada), Ltd., British Columbia corporation (“ImmunoCanada”), ImmunoPrecise Antibodies (Europe) BV, a company incorporated in the Netherlands (“ImmunoDutch”), and BioStrand B.V., a company incorporated in Belgium ((“BioStrand”) and collectively with ImmunoCanada and ImmunoDutch, the “Guaran

This Policy shall be binding upon and enforceable against all Covered Executives and their beneficiaries, heirs, executors, administrators or other legal representatives

Exhibit 97.1 IMMUNOPRECISE ANTIBODIES LTD. INCENTIVE COMPENSATION RECOVERY POLICY 1. Introduction. The Board of Directors of ImmunoPrecise Antibodies Ltd. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company's compensation philosophy. The Board has

As of the date of the Annual Report on Form 20-F (the “

Exhibit 2.1 As of the date of the Annual Report on Form 20-F (the “Annual Report”) of which this Exhibit 2.1 is a part, ImmunoPrecise Antibodies Ltd. (the “Company”) has only one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: the Company’s common shares (the “Common Shares”). Description of Common Shares The following description of the Common S

CERTIFICATION

Exhibit 12.2 CERTIFICATION I, Joseph Scheffler, certify that: 1. I have reviewed this annual report on Form 20-F of ImmunoPrecise Antibodies Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading wi

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We have issued our report dated July 29, 2025, with respect to the consolidated financial statements included in this Annual Report on Form 20-F of ImmunoPrecise Antibodies Ltd., as filed with the United States Securities and Exchange Commission, for the year ended April 30, 2025. We also consent to the incorporation by referenc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF

CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of ImmunoPrecise Antibodies Ltd. (the “Company”) on Form 20-F for the period ended April 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jennifer Bath, Chief Executive Officer of the Com

MATERIAL TRANSFER AND EVALUATION AGREEMENT Biotheus, Inc. Talem Therapeutics LLC ImmunoPrecise Antibodies (USA), Ltd. ImmunoPrecise Antibodies (Europe) B.V. (Oss) ImmunoPrecise Antibodies (Europe) B.V. (Utrecht) BioStrand BV Confidential Disclosure

MATERIAL TRANSFER AND EVALUATION AGREEMENT THIS MATERIAL TRANSFER AND EVALUATION AGREEMENT (the “MTE Agreement,” and together with its Appendices, the “MTEA”) is made as of the date of the last signature below (the “Effective Date”) by and between Biotheus, Inc.

ImmunoPrecise Antibodies (IPA) Reports Record Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA

ImmunoPrecise Antibodies (IPA) Reports Record Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA AUSTIN, Texas, July 29, 2025 – ImmunoPrecise Antibodies Ltd.

July 29, 2025

Exhibit 16.1 July 29, 2025 U.S. Securities and Exchange Commission Office of the Chief Accountant 100 F Street, NE Washington, DC 20549 Re: ImmunoPrecise Antibodies Ltd. File No. 001-39530 Dear Sir or Madam: We have read Item 16F of Form 20-F of ImmunoPrecise Antibodies Ltd. dated July 29, 2025, and agree with the statements concerning our Firm contained therein. Very truly yours, /s/ GRANT THORNT

ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic

ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic AUSTIN, Texas   - ImmunoPrecise Antibodies Ltd.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025. Commission File Number: 001-39530

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check mar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025. Commission File Number: 001-39530

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check mar

ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board

ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board AUSTIN, Texas   - ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement

ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement AUSTIN, Texas  – ImmunoPrecise Antibodies Ltd.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025. Commission File Number: 001-39530

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check mar

ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors

ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors AUSTIN, Texas  – ImmunoPrecise Antibodies Ltd.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025. Commission File Number: 001-39530

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check mar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025. Commission File Number: 001-39530

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check mar

ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data

ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data New benchmark confirms LENSai’s ability to accurately predict binding on 17 previously unseen antibody-antigen complexes, achieving near-crystallography precision without prior training data.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025. Commission File Number: 001-39530

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check mar

ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ platform powered by patented HYFT® Technology Follow-Up to June 5, 2025, Announcement Demonstrates Validated Vaccine Can

ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ platform powered by patented HYFT® Technology Follow-Up to June 5, 2025, Announcement Demonstrates Validated Vaccine Candidate with Strong Translational Potential AUSTIN, Texas — ImmunoPrecise (NASDAQ: IPA), a leader in AI-driven biotherapeutics, provides a significant update following its June 5, 2025, press release ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery.

AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies Breakthrough in AI-powered drug discovery validates HYFT®-driven peptide design, with broad potential across multiple therapeutic areas

AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies Breakthrough in AI-powered drug discovery validates HYFT®-driven peptide design, with broad potential across multiple therapeutic areas AUSTIN, Texas – ImmunoPrecise Antibodies Ltd.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025. Commission File Number: 001-39530

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check mar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025. Commission File Number: 001-39530

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check mar

ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery LENSai™ powered by HYFT® technology Identifies a single multi-factorial target conserved across all dengue serotypes.

ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery LENSai™ powered by HYFT® technology Identifies a single multi-factorial target conserved across all dengue serotypes.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025. Commission File Number: 001-39530 I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check mark

ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts

ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts AUSTIN, Texas, May 21, 2025 - ImmunoPrecise Antibodies Ltd.

IPA’s LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed

IPA’s LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed AUSTIN, Texas - ImmunoPrecise Antibodies Ltd.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025. Commission File Number: 001-39530 I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check mark

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2025. Commission File Number: 001-39530

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check ma

ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods

ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods AUSTIN, Texas - ImmunoPrecise Antibodies Ltd.

IPA to Present at The Microcap Conference 2025

IPA to Present at The Microcap Conference 2025 VICTORIA, British Columbia-(BUSINESS WIRE)-December 19, 2024-IPA (IMMUNOPRECISE ANTIBODIES LTD.

ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period

ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period AUSTIN, Texas-(BUSINESS WIRE)-February 20, 2025-ImmunoPrecise Antibodies Ltd.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2025. Commission File Number: 001-39530

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check ma

IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy

IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy AUSTIN, Texas-(BUSINESS WIRE)-February 26, 2025-ImmunoPrecise Antibodies Ltd.

IPA Gives Update on the Status of its At-the-Market Program

IPA Gives Update on the Status of its At-the-Market Program AUSTIN, Texas-April 9, 2025-ImmunoPrecise Antibodies Ltd.

IPA to Present at The Benchmark Company’s Upcoming Discovery One-on One Investor Conference

IPA to Present at The Benchmark Company’s Upcoming Discovery One-on One Investor Conference VICTORIA, British Columbia-(BUSINESS WIRE)-December 4, 2024-IPA (IMMUNOPRECISE ANTIBODIES LTD.

Three Months Ended ($)

IMMUNOPRECISE ANTIBODIES LTD. MANAGEMENT DISCUSSION AND ANALYSIS FOR THE THREE AND NINE MONTHS ENDED JANUARY 31, 2025 Exhibit 99.1 The following Management’s Discussion and Analysis (“MD&A”) should be read in conjunction with the unaudited condensed interim consolidated financial statements of ImmunoPrecise Antibodies Ltd. (“the Company”, “ImmunoPrecise” or “IPA”) for the three and nine months end

Form 52-109F2 Certification of Interim Filings Full Certificate

Exhibit 99.3 Form 52-109F2 Certification of Interim Filings Full Certificate I, Jennifer Bath, Chief Executive Officer, ImmunoPrecise Antibodies, Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of ImmunoPrecise Antibodies, Ltd. (the “issuer”) for the interim period ended January, 31, 2025. 2. No misrepresentati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2025. Commission File Number: 001-39530

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check ma

IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the three and nine months ended January 31, 2025 and 2024 (Unaudited - Expressed in Canadian Dollars)

Exhibit 99.2 IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the three and nine months ended January 31, 2025 and 2024 (Unaudited - Expressed in Canadian Dollars) IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Unaudited - Expressed in Canadian dollars) (in thousands) Note January 31, 2025 $ April 30, 2024 $ ASSET

Form 52-109F2 Certification of Interim Filings Full Certificate

Exhibit 99.4 Form 52-109F2 Certification of Interim Filings Full Certificate I, , Interim Chief Financial Officer, ImmunoPrecise Antibodies, Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of ImmunoPrecise Antibodies, Ltd. (the “issuer”) for the interim period ended January, 31, 2025. 2. No misrepresentations:

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 Secures $8-$10M Strategic Partnership Scales AI Infrastructure Collaborations with Vultr and Leading Providers of Advanced GPU

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 Secures $8-$10M Strategic Partnership Scales AI Infrastructure Collaborations with Vultr and Leading Providers of Advanced GPU technologies to Accelerate de novo Drug Discovery.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2025. Commission File Number: 001-39530

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check ma

Programs to be Driven Through Patented AI Technology and Advanced Proprietary B Cell Platforms Partnership advances next-generation ADCs and bispecific antibodies to address unmet medical needs

ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2025. Commission File Number: 001-39530

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check ma

IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025 The Company to host an earnings conference call via webcast

IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025 The Company to host an earnings conference call via webcast AUSTIN, Texas – ImmunoPrecise Antibodies Ltd.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2025. Commission File Number: 001-39530

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check ma

ImmunoPrecise Antibodies Announces Key Leadership Changes

ImmunoPrecise Antibodies Announces Key Leadership Changes AUSTIN, TEXAS, – ImmunoPrecise Antibodies (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, is pleased to announce key leadership updates, including the appointment of Kamil Isaev to its Board of Directors and Joseph Scheffler as Interim Chief Financial Officer (CFO).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025. Commission File Number: 001-39

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check

ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture IPA Successfully Executes Strategic Capital Initiatives, Strengthening Financial Position for Growth

ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture IPA Successfully Executes Strategic Capital Initiatives, Strengthening Financial Position for Growth AUSTIN, Texas – ImmunoPrecise Antibodies Ltd.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025. Commission File Number: 001-39

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check

ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture IPA Successfully Executes Strategic Capital Initiatives, Strengthening Financial Position for Growth

ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture IPA Successfully Executes Strategic Capital Initiatives, Strengthening Financial Position for Growth   AUSTIN, Texas – ImmunoPrecise Antibodies Ltd.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025. Commission File Number: 001-395

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check

IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment. AUSTIN, Texas – ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) has developed a new class of GLP-1 therapies entirely through artifi

IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025. Commission File Number: 001-395

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check

ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation

ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation AUSTIN, Texas – ImmunoPrecise Antibodies Ltd.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025. Commission File Number: 001-395

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by ch

FORM 51-102F3 MATERIAL CHANGE REPORT

FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company ImmunoPrecise Antibodies Ltd.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025. Commission File Number: 001-395

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by ch

ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases

ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases VICTORIA, BRITISH COLUMBIA (CANADA), December 23, 2024 – ImmunoPrecise Antibodies Ltd.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024. Commission File Number: 001-39

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by c

Form 52-109F2 Certification of Interim Filings Full Certificate

Exhibit 99.4 Form 52-109F2 Certification of Interim Filings Full Certificate I, Kristin Taylor, Chief Financial Officer, ImmunoPrecise Antibodies, Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of ImmunoPrecise Antibodies, Ltd. (the “issuer”) for the interim period ended October 31, 2024. 2. No misrepresentati

Three Months Ended ($)

IMMUNOPRECISE ANTIBODIES LTD. MANAGEMENT DISCUSSION AND ANALYSIS FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2024 Exhibit 99.1 The following Management’s Discussion and Analysis (“MD&A”) should be read in conjunction with the unaudited condensed interim consolidated financial statements of ImmunoPrecise Antibodies Ltd. (“the Company”, “ImmunoPrecise” or “IPA”) for the three and six months ended

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 Delivers $6.1 Million Q2 Revenue and Announces Strategic Plan to Reshape Biotech and AI-Driven Drug Discovery

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 Delivers $6.

CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of ImmunoPrecise Antibodies Ltd. (the "Company") on Form 20-F/A for the period ended April 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Kristin Taylor, Chief Financial Officer of the Company, cert

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A (Amendment No. 1) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURI

CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of ImmunoPrecise Antibodies Ltd. (the "Company") on Form 20-F/A for the period ended April 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Jennifer Bath, Chief Executive Officer of the Company, certi

CERTIFICATION REQUIRED BY RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934

CERTIFICATION REQUIRED BY RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 I, Jennifer Bath, certify that: 1.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024. Commission File Number: 001-39

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by c

Form 52-109F2 Certification of Interim Filings Full Certificate

Exhibit 99.3 Form 52-109F2 Certification of Interim Filings Full Certificate I, Jennifer Bath, Chief Executive Officer, ImmunoPrecise Antibodies, Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of ImmunoPrecise Antibodies, Ltd. (the “issuer”) for the interim period ended October 31, 2024. 2. No misrepresentatio

IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the three and six months ended October 31, 2024 and 2023 (Unaudited - Expressed in Canadian Dollars)

Exhibit 99.2 IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the three and six months ended October 31, 2024 and 2023 (Unaudited - Expressed in Canadian Dollars) IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Unaudited - Expressed in Canadian dollars) (in thousands) Note October 31, 2024 $ April 30, 2024 $ ASSETS

CERTIFICATION REQUIRED BY RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934

CERTIFICATION REQUIRED BY RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 I, Kristin Taylor, certify that: 1.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by c

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024. Commission File Number: 001-39

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by c

IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on December 10, 2024 The Company to host an earnings conference call via webcast

IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on December 10, 2024 The Company to host an earnings conference call via webcast VICTORIA, BRITISH COLUMBIA (CANADA), December 3, 2024 – IPA (IMMUNOPRECISE ANTIBODIES LTD.

Report of Voting Results Submitted Pursuant to Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations

Report of Voting Results Submitted Pursuant to Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations In accordance with Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations, this report describes the matters voted upon and the outcome of the votes at the annual general meeting of shareholders of ImmunoPrecise Antibodies Ltd. (the "Corporation") he

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024. Commission File Number: 001-39

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by c

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024. Commission File Number: 001-39

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by c

$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies Innovative Antibodies Show Promise for Antibody-Drug Conjugate (ADC) Development, Paving the Way for Transformative Cancer Treatme

$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies Innovative Antibodies Show Promise for Antibody-Drug Conjugate (ADC) Development, Paving the Way for Transformative Cancer Treatments VICTORIA, BRITISH COLUMBIA (CANADA), November 13, 2024 – ImmunoPrecise Antibodies Ltd.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024. Commission File Number: 001-39

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by c

ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation

ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation VICTORIA, BRITISH COLUMBIA (CANADA), November 4, 2024 – ImmunoPrecise Antibodies Ltd.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024. Commission File Number: 001-395

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by ch

ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology Rabbit B Cell Select® Platform Yields Novel Antibodies for Studying Age-Related Mitochondrial Dysfunction

ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology Rabbit B Cell Select® Platform Yields Novel Antibodies for Studying Age-Related Mitochondrial Dysfunction VICTORIA, BRITISH COLUMBIA (CANADA), October 28, 2024 – ImmunoPrecise Antibodies Ltd.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X (

ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024

ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024 VICTORIA, BRITISH COLUMBIA (CANADA), October 21, 2024 – ImmunoPrecise Antibodies Ltd.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024. Commission File Number: 001-395

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by ch

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8

To: All Canadian Securities Regulatory Authorities

Date: October 10, 2024 510 Burrard St, 3rd Floor Vancouver BC, V6C 3B9 www.computershare.com To: All Canadian Securities Regulatory Authorities AMENDED - SEE HIGHLIGHTED Subject: IMMUNOPRECISE ANTIBODIES LTD. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Annual General Meeting Record Date for Notice of Mee

ImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design University of Washington’s Baker Lab and Google DeepMind Redefine Protein Science, Paving the Way for AI-Driven Biotherapeutics

ImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design University of Washington’s Baker Lab and Google DeepMind Redefine Protein Science, Paving the Way for AI-Driven Biotherapeutics VICTORIA, BRITISH COLUMBIA (CANADA), October 10, 2024 – ImmunoPrecise Antibodies Ltd.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024. Commission File Number: 001-395

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by ch

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024. Commission File Number: 001-395

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by ch

ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus Talem Therapeutics' Antibody Asset to be Evaluated for Bispecific Development Against Solid Tumors

ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus Talem Therapeutics' Antibody Asset to be Evaluated for Bispecific Development Against Solid Tumors VICTORIA, BRITISH COLUMBIA (CANADA), ZHUHAI, (CHINA), October 2, 2024 – ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments Rabbit B Cell Select® Drives Clinical Breakthroughs in Cancer Treatment

ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments Rabbit B Cell Select® Drives Clinical Breakthroughs in Cancer Treatment VICTORIA, BRITISH COLUMBIA (CANADA), September 26, 2024 – ImmunoPrecise Antibodies Ltd.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024. Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by

To: All Canadian Securities Regulatory Authorities

Date: September 20, 2024 510 Burrard St, 3rd Floor Vancouver BC, V6C 3B9 www.computershare.com To: All Canadian Securities Regulatory Authorities Subject: IMMUNOPRECISE ANTIBODIES LTD. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Annual General and Special Meeting Record Date for Notice of Meeting : Octob

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X

IMMUNOPRECISE ANTIBODIES LTD. 3204 - 4464 Markham Street Victoria, British Columbia V8Z 7X8 September 17, 2024 Form 51-102F6 STATEMENT OF EXECUTIVE COMPENSATION (for the financial year ended April 30, 2024)

IMMUNOPRECISE ANTIBODIES LTD. 3204 - 4464 Markham Street Victoria, British Columbia V8Z 7X8 September 17, 2024 Form 51-102F6 STATEMENT OF EXECUTIVE COMPENSATION (for the financial year ended April 30, 2024) This Statement of Executive Compensation is filed by ImmunoPrecise Antibodies Ltd. (“IPA” or the “Company”) pursuant to National Instrument 51‐102 – Continuous Disclosure Obligations under Cana

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by

Form 52-109F2 Certification of Interim Filings Full Certificate

Exhibit 99.4 Form 52-109F2 Certification of Interim Filings Full Certificate I, Kristin Taylor, Chief Financial Officer, ImmunoPrecise Antibodies, Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of ImmunoPrecise Antibodies, Ltd. (the “issuer”) for the interim period ended July, 31, 2024. 2. No misrepresentation

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 Achieves $5.3 Million First Quarter Revenue, Reaches Milestone Developing Antibodies End-to-End Using LENSai

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 Achieves $5.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by c

IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the three months ended July 31, 2024 and 2023 (Unaudited - Expressed in Canadian Dollars)

Exhibit 99.2 IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the three months ended July 31, 2024 and 2023 (Unaudited - Expressed in Canadian Dollars) IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Unaudited - Expressed in Canadian dollars) (in thousands) Note July 31, 2024 $ April 30, 2024 $ ASSETS Current asset

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024. Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by

Three Months Ended ($)

IMMUNOPRECISE ANTIBODIES LTD. MANAGEMENT DISCUSSION AND ANALYSIS FOR THE THREE MONTHS ENDED JULY 31, 2024 Exhibit 99.1 The following Management’s Discussion and Analysis (“MD&A”) should be read in conjunction with the unaudited condensed interim consolidated financial statements of ImmunoPrecise Antibodies Ltd. (the "Company”, “ImmunoPrecise” or “IPA”) for the three months ended July 31, 2024, tog

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by

Form 52-109F2 Certification of Interim Filings Full Certificate

Exhibit 99.3 Form 52-109F2 Certification of Interim Filings Full Certificate I, Jennifer Bath, Chief Executive Officer, ImmunoPrecise Antibodies, Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of ImmunoPrecise Antibodies, Ltd. (the “issuer”) for the interim period ended July, 31, 2024. 2. No misrepresentations

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024. Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by

IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024 The Company to host an earnings conference call via webcast.

IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024 The Company to host an earnings conference call via webcast.

ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York

ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York VICTORIA, BRITISH COLUMBIA (CANADA), August 26, 2024 – ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), is pleased to announce that it will be attending H.C. Wainwright's 26th Annual Global Investment Conference (the "Global Investment Conference"). The Company's m

ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements

ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements VICTORIA, BRITISH COLUMBIA (CANADA), August 23, 2024 – ImmunoPrecise Antibodies Ltd.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024. Commission File Number: 001-3953

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by che

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024. Commission File Number: 001-3953

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by che

ImmunoPrecise Antibodies Successfully Engineers in silico Antibodies to Elusive Tumor Protein Using Its Patented LENSai Technology

ImmunoPrecise Antibodies Successfully Engineers in silico Antibodies to Elusive Tumor Protein Using Its Patented LENSai Technology Engineering antibodies in silico using LENSai™ marks a significant milestone toward the complete de novo design of antibodies, aligning with IPA's vision to make groundbreaking and safer therapeutics instantly accessible and affordable.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024. Commission File Number: 001-3953

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by che

Calculation of Filing Fee Table Form F-3 (Form Type) ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Table Form F-3 (Form Type) ImmunoPrecise Antibodies Ltd.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMUNOPRECISE ANTIBODIES LTD. (Exact name of registrant as specified in its charter) Not Applicable (Translation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMUNOPRECISE ANTIBODIES LTD. (Exact name of registrant as specified in its charter) Not Applicable (Translation of Registrant's name into English) British Columbia (Province or Other Jurisdiction of Incorporation or Organization) Not Applicable (I.R.S. Employer

ImmunoPrecise Antibodies Ltd. Up to U.S.$8,800,000 Common Shares

AMENDMENT NO. 1 DATED JULY 29, 2024 to Prospectus Supplement dated February 23, 2024 (To Prospectus dated July 14, 2023) Filed Pursuant to Rule 424(b)(5) Registration No. 333-273197 ImmunoPrecise Antibodies Ltd. Up to U.S.$8,800,000 Common Shares This Amendment No. 1 to Prospectus Supplement (this "Amendment") amends our prospectus supplement dated February 23, 2024 (the "Prospectus Supplement). T

CERTIFICATION

Exhibit 12.2 CERTIFICATION I, Kristin Taylor, certify that: 1. I have reviewed this annual report on Form 20-F of ImmunoPrecise Antibodies Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024 Achieves Record $24.5 Million Revenue in FY 2024, Showcases Technological Advancements Expands Laboratory Capabilities and Laun

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024 Achieves Record $24.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF

CERTIFICATION

Exhibit 12.1 CERTIFICATION I, Jennifer Bath, certify that: 1. I have reviewed this annual report on Form 20-F of ImmunoPrecise Antibodies Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with

CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of ImmunoPrecise Antibodies Ltd. (the “Company”) on Form 20-F for the period ended April 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Kristin Taylor, Chief Financial Officer of the Co

We have issued our report dated July 29, 2024, with respect to the consolidated financial statements included in this Annual Report on Form 20-F of ImmunoPrecise Antibodies Ltd. (the “Company”) for the year ended April 30, 2024, as filed with the Uni

Exhibit 15.1 We have issued our report dated July 29, 2024, with respect to the consolidated financial statements included in this Annual Report on Form 20-F of ImmunoPrecise Antibodies Ltd. (the “Company”) for the year ended April 30, 2024, as filed with the United States Securities and Exchange Commission. We consent to the incorporation by reference of our report into the Registration Statement

REGISTRATION RIGHTS AGREEMENT

Exhibit 4.6 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of July 16, 2024 is made by and between YA II PN, LTD., a Cayman Islands exempt limited partnership (the “Investor”), and IMMUNOPRECISE ANTIBODIES LTD., a British Columbia corporation (the “Company”). The Investor and the Company may be referred to herein individually as a “Party” and collecti

SECURITIES PURCHASE AGREEMENT

Exhibit 4.5 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of July 16, 2024, is between IMMUNOPRECISE ANTIBODIES LTD., a British Columbia corporation, with principal executive offices located at 3204-4464 Markham Street, Victoria, BC V8Z 7X8 (the “Company”), and each of the investors listed on the Schedule of Buyers attached as Schedule I hereto (indi

IMMUNOPRECISE ANTIBODIES LTD. INCENTIVE COMPENSATION RECOVERY POLICY

Exhibit 97.1 IMMUNOPRECISE ANTIBODIES LTD. INCENTIVE COMPENSATION RECOVERY POLICY 1. Introduction. The Board of Directors of ImmunoPrecise Antibodies Ltd. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company's compensation philosophy. The Board has

IMMUNOPRECISE ANTIBODIES LTD. Convertible Debenture

Exhibit 2.2 THE SECURITIES REPRESENTED BY THIS CERTIFICATE AND THOSE SECURITIES INTO WHICH THEY ARE CONVERTIBLE HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES AND THOSE SECURITIES INTO WHICH THEY ARE CONVERTIBLE HAVE BEEN ACQUIRED SOLELY FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWAR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2024. Commission File Number: 001-39530

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by check

As of the date of the Annual Report on Form 20-F (the “

Exhibit 2.1 As of the date of the Annual Report on Form 20-F (the “Annual Report”) of which this Exhibit 2.1 is a part, ImmunoPrecise Antibodies Ltd. (the “Company”) has only one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: the Company’s common shares (the “Common Shares”). Description of Common Shares The following description of the Common S

CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of ImmunoPrecise Antibodies Ltd. (the “Company”) on Form 20-F for the period ended April 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jennifer Bath, Chief Executive Officer of the Com

GLOBAL GUARANTY AGREEMENT

Exhibit 4.7 GLOBAL GUARANTY AGREEMENT This Guaranty is made as of July 16, 2024 by ImmunoPrecise Antibodies (Canada), Ltd., British Columbia corporation (“ImmunoCanada”), ImmunoPrecise Antibodies (Europe) BV, a company incorporated in the Netherlands (“ImmunoDutch”), and BioStrand B.V., a company incorporated in Belgium ((“BioStrand”) and collectively with ImmunoCanada and ImmunoDutch, the “Guaran

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2024. Commission File Number: 001-39530

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by check

ImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year End 2024 The Company to host an earnings conference call via webcast

ImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year End 2024 The Company to host an earnings conference call via webcast VICTORIA, BRITISH COLUMBIA, July 23, 2024 - ImmunoPrecise Antibodies Ltd.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Ad

2

ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2024 on July 25th, 2024 The Company to host an earnings conference call via webcast

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2024 on July 25th, 2024 The Company to host an earnings conference call via webcast VICTORIA, BRITISH COLUMBIA (CANADA), July 15, 2024 – IPA (IMMUNOPRECISE ANTIBODIES LTD.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2024. Commission File Number: 001-39530

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by check

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024. Commission File Number: 001-39530

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by check

ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer

ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer VICTORIA, BRITISH COLUMBIA (CANADA), June 27, 2024 – ImmunoPrecise Antibodies Ltd.

IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™

IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™ VICTORIA, BRITISH COLUMBIA (CANADA), June 25, 2024 – ImmunoPrecise Antibodies Ltd.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024. Commission File Number: 001-39530

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by check

ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology

ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology VICTORIA, British Columbia, June 12, 2024 - ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("ImmunoPrecise" or "IPA" or the "Company"), a leader in AI-driven biotherapeutic research and technology, today announces that its subsidiary, BioStrand, has been honored with the pre

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024. Commission File Number: 001-395

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Ad

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Ad

BioStrand, ImmunoPrecise Antibodies' Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery

BioStrand, ImmunoPrecise Antibodies' Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery -BioStrand now offers a Customizable Application Programming Interface (API) with its new software offering, LENSai API, featuring the ability to integrate sizable databases and electronic health records with large language models.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024. Commission File Number: 001-395

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Ad

IPA's Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR) Dirk Van Hyfte MD, PhD, Head of Technology, IPA, to present live demonstration at the InterSystems Global Summit 2024 June 9-12, 2024 - Nat

IPA's Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR) Dirk Van Hyfte MD, PhD, Head of Technology, IPA, to present live demonstration at the InterSystems Global Summit 2024 June 9-12, 2024 - National Harbor, Maryland VICTORIA, BRITISH COLUMBIA (CANADA), June 03, 2024 - IPA (IMMUNOPRECISE ANTIBODIES LTD.

InterSystems and IPA's Subsidiary BioStrand Unveil the Innovative Integration of Vector Search with LENSai for AI- Driven Healthcare Applications

InterSystems and IPA's Subsidiary BioStrand Unveil the Innovative Integration of Vector Search with LENSai for AI- Driven Healthcare Applications VICTORIA, BRITISH COLUMBIA (CANADA), March 28, 2024 - IPA (IMMUNOPRECISE ANTIBODIES LTD.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-3953

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Add

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (A

IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments Significant throughput of LSA to advance IPA's diversity- and data-driven drug development and to enrich LENSai™.

IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments Significant throughput of LSA to advance IPA's diversity- and data-driven drug development and to enrich LENSai™.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by chec

IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the three and nine months ended January 31, 2024 and 2023 (Unaudited - Expressed in Canadian Dollars)

Exhibit 99.2 IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the three and nine months ended January 31, 2024 and 2023 (Unaudited - Expressed in Canadian Dollars) IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Unaudited - Expressed in Canadian dollars) (in thousands) Note January 31, 2024 $ April 30, 2023 $ ASSET

Form 52-109F2 Certification of Interim Filings Full Certificate

Exhibit 99.3 Form 52-109F2 Certification of Interim Filings Full Certificate I, Jennifer Bath, Chief Executive Officer, ImmunoPrecise Antibodies, Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of ImmunoPrecise Antibodies, Ltd. (the “issuer”) for the interim period ended January, 31, 2024. 2. No misrepresentati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (A

Three Months Ended ($)

IMMUNOPRECISE ANTIBODIES LTD. MANAGEMENT DISCUSSION AND ANALYSIS FOR THE THREE AND NINE MONTHS ENDED JANUARY 31, 2024 Exhibit 99.1 The following Management’s Discussion and Analysis (“MD&A”) should be read in conjunction with the unaudited condensed interim consolidated financial statements of ImmunoPrecise Antibodies Ltd. (“the Company” or “IPA”) for the three and nine months ended January 31, 20

Form 52-109F2 Certification of Interim Filings Full Certificate

Exhibit 99.4 Form 52-109F2 Certification of Interim Filings Full Certificate I, Kristin Taylor, Chief Financial Officer, ImmunoPrecise Antibodies, Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of ImmunoPrecise Antibodies, Ltd. (the “issuer”) for the interim period ended January, 31, 2024. 2. No misrepresentat

IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024* IPA reports a fourth consecutive quarter of increased revenue.

IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024* IPA reports a fourth consecutive quarter of increased revenue.

IPA's subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology Dirk Van Hyfte MD, PhD, Co-Founder and Head of Innovation of BioStrand, to present findings live next

IPA's subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology Dirk Van Hyfte MD, PhD, Co-Founder and Head of Innovation of BioStrand, to present findings live next week at the HIMSS24 conference in Orlando, Florida VICTORIA, BRITISH COLUMBIA (CANADA), March 7, 2024 - IPA (IMMUNOPRECISE ANTIBODIES LTD.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-3953

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Translation of registrant's name into English) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Addres

IPA / ImmunoPrecise Antibodies Ltd. / INGALLS & SNYDER LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. )* IMMUNOPRECISE ANTIBODIES LTD. - (Name of Issuer) COMMON STOCK - (Title of Class of Securities) 45257F200 - (CUSIP Number) 02/13/2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8

ImmunoPrecise Antibodies Ltd. Up to U.S.$60,000,000 Common Shares

PROSPECTUS SUPPLEMENT (To Prospectus dated July 14, 2023) Filed Pursuant to Rule 424(b)(5) Registration No.

SALES AGREEMENT

SALES AGREEMENT February 23, 2024 CLEAR STREET LLC 4 World Trade Center, Floor 45 New York, New York 10007 Ladies and Gentlemen: ImmunoPrecise Antibodies Ltd.